Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
| Business Activity | PASS |
| Debt Ratio (0.31%) | PASS |
| Cash Ratio (0.01%) | PASS |
| Receivables Ratio (0.06%) | PASS |
| Revenue Ratio (0.01%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-07-29 | 0.68 | Pending | -- |
| 2026-05-05 | 0.52 | 0.47 | -9.5% |
| 2026-02-03 | 0.57 | 0.66 | +16.2% |
| 2025-11-04 | 0.63 | 0.87 | +37.4% |
| 2025-08-05 | 0.36 | 0.51 | +41.6% |
| 2025-04-29 | 0.67 | 0.92 | +36.5% |
| 2025-02-04 | 0.46 | 0.63 | +37.2% |
| 2024-10-29 | 0.61 | 1.06 | +73.3% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $14.4B | $2.7B | $5.5B | $10.9B | $4.1B | 0.47 |
| 2025-12-31 | $17.6B | -$1.6B | $756.0M | $12.3B | $3.5B | -0.29 |
| 2025-09-30 | $16.7B | $3.5B | $5.6B | $12.5B | $4.1B | 0.62 |
| 2025-06-30 | $14.7B | $2.9B | $5.3B | $10.9B | $3.8B | 0.51 |
| 2025-03-31 | $13.7B | $3.0B | $5.1B | $10.9B | $4.4B | 0.52 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-03-03 | DAMICO JENNIFER B. | Officer | 21,719 | -- |
| 2026-02-25 | SAHNI PAYAL | Officer | 56,888 | $1.9M |
| 2026-02-25 | MCDERMOTT MICHAEL | Officer | 37,925 | $1.3M |
| 2026-02-25 | DAMICO JENNIFER B. | Officer | 17,558 | $593.8K |
| 2026-02-25 | BOURLA ALBERT | Chief Executive Officer | 491,626 | $16.6M |
| 2026-02-25 | FONSECA LIDIA PH.D. | Officer | 56,888 | $1.9M |
| 2026-02-25 | LANKLER DOUGLAS M | Officer | 122,907 | $4.2M |
| 2026-02-25 | BOSHOFF CHRISTOFFEL | Officer | 13,383 | -- |
| 2025-03-04 | DAMICO JENNIFER B. | Officer | 2,500 | $64.8K |
| 2025-03-04 | DAMICO JENNIFER B. | Officer | 5,583 | -- |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 498.3M | $12.9B | 0.1% |
| Vanguard Capital Management LLC | 369.4M | $9.6B | 0.1% |
| State Street Corporation | 301.6M | $7.8B | 0.1% |
| Geode Capital Management, LLC | 133.6M | $3.5B | 0.0% |
| Vanguard Portfolio Management LLC | 116.7M | $3.0B | 0.0% |
| Fisher Asset Management, LLC | 105.0M | $2.7B | 0.0% |
| Morgan Stanley | 92.7M | $2.4B | 0.0% |
| Northern Trust Corporation | 62.0M | $1.6B | 0.0% |
| Massachusetts Financial Services Co. | 56.9M | $1.5B | 0.0% |
| State Farm Mutual Automobile Insurance Co | 54.5M | $1.4B | 0.0% |
$199.6B
1.70
0.305
27
$63.3B
$64.7B
-10.1%
6.7%
2.45
3.98
0.0%
75,000
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-07-29 | $0.68 | Pending | — |
| 2026-05-05 | $0.52 | $0.47 | -9.5% |
| 2026-02-03 | $0.57 | $0.66 | +16.2% |
| 2025-11-04 | $0.63 | $0.87 | +37.4% |
| 2025-08-05 | $0.36 | $0.51 | +41.6% |
| 2025-04-29 | $0.67 | $0.92 | +36.5% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($29.19, 27 analysts) | |||
| 10 | $256.80 | +$35.10 (14%) | 0.9R |
| 50 | $1,284.00 | +$175.50 (14%) | 0.9R |
| 100 | $2,568.00 | +$351.00 (14%) | 0.9R |
| To Fair Value ($34.12) | |||
| 10 | $256.80 | +$84.40 (33%) | 2.2R |
| 50 | $1,284.00 | +$422.00 (33%) | 2.2R |
| 100 | $2,568.00 | +$844.00 (33%) | 2.2R |
- Elevated short interest (3.98 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| XLV | 0.619 |
| AMGN | 0.564 |
| BMY | 0.540 |
| DHR | 0.534 |
| NVS | 0.533 |
| Ticker | Correlation |
|---|---|
| ANTA | -0.121 |
| JPSWY | -0.111 |
| VRAYQ | -0.109 |
| FLY | -0.109 |
| 6146.T | -0.108 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.